Parsonage-Turner syndrome following COVID-19 vaccination

INTRODUCTION
Parsonage-Turner syndrome (PTS), also known as neuralgic amyotrophy, is an acute idiopathic brachial neuritis, typically characterised by acute onset of excruciating pain followed by weakness and wasting in the upper limb. Antecedent events such as infection, exercise, trauma, surgery and vaccination are reported in approximately 50% of affected individuals. PTS has been reported following COVID-19 vaccination, but the current literature is limited to several case reports and a passive reporting system. Herein, we report on the clinical, radiological and laboratory features of 12 cases with PTS post COVID-19 vaccination.

METHODS
We reviewed medical records of the patients who were diagnosed with PTS following COVID-19 vaccination in three referral hospitals (Seoul, South Korea) between June and October 2021. We collected and analysed the detailed clinical information as follows: the type and order (in case of different types) of COVID-19 vaccine, laterality of symptom presentation, timeline regarding the vaccination, symptom onset and nadir, clinical presentation, motor grade at nadir, the results of electrodiagnosis, brachial plexus MRI, cerebrospinal fluid (CSF) analysis, treatment regimen and the outcomes.

RESULTS
We identified 12 patients (7 men and 5 women) who developed PTS after a receipt of COVID-19 vaccine. Clinical features of the patients are summarised in Table 1. CSF analysis showed albuminocytological dissociation in all three tested patients (patients 1, 3 and 12). We administered oral or intravenous corticosteroid in all patients but three: two patients showed rapid clinical improvement (patients 5 and 7), and one patient refused to receive the treatment.

<table>
<thead>
<tr>
<th>No</th>
<th>Sex/age (years)</th>
<th>Vaccine (dose)</th>
<th>Laterality</th>
<th>Days from vaccination to symptom onset/ nadir</th>
<th>Weakest muscle strength at nadir (MRC)</th>
<th>MRI</th>
<th>CSF analysis*</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M/31</td>
<td>Janssen</td>
<td>Ipsilateral</td>
<td>6/7</td>
<td>III</td>
<td>WBC 0, protein 70</td>
<td>None</td>
<td>Full recovery by week 1</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>M/37</td>
<td>Janssen</td>
<td>Ipsilateral</td>
<td>14/14</td>
<td>IV+</td>
<td>Normal</td>
<td>Oral prednisolone, gabapentin</td>
<td>Near-full recovery by week 10</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>M/71</td>
<td>AstraZeneca (first dose)</td>
<td>Ipsilateral</td>
<td>16/35</td>
<td>III</td>
<td>Signal changes and enlargement from the C8 root to the inferior trunk, prominent ipsilateral cervical and axillary lymph nodes</td>
<td>WBC 2, protein 57</td>
<td>Oral prednisolone, gabapentin</td>
<td>Poor recovery by week 15</td>
</tr>
<tr>
<td>4</td>
<td>M/63</td>
<td>AstraZeneca (first dose)</td>
<td>Ipsilateral</td>
<td>14/14</td>
<td>III</td>
<td>ND</td>
<td>None</td>
<td>Poor recovery by week 4, lost to follow-up thereafter</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>F/85</td>
<td>AstraZeneca (first dose)</td>
<td>Ipsilateral</td>
<td>5/6</td>
<td>III</td>
<td>Prominent ipsilateral axillary lymph nodes</td>
<td>ND</td>
<td>None</td>
<td>Full recovery within 2 months</td>
</tr>
<tr>
<td>6</td>
<td>M/81</td>
<td>AstraZeneca (second dose)</td>
<td>Ipsilateral</td>
<td>2/3</td>
<td>II</td>
<td>Signal changes and enlargement from the C8 root to the inferior trunk and medial cord, prominent cervical and axillary lymph nodes</td>
<td>ND</td>
<td>Oral prednisolone</td>
<td>Partial recovery by month 5</td>
</tr>
<tr>
<td>7</td>
<td>F/31</td>
<td>Cross-vaccination (AstraZeneca and then Pfizer)</td>
<td>Ipsilateral</td>
<td>2/10</td>
<td>IV</td>
<td>Prominent ipsilateral axillary and cervical lymph nodes</td>
<td>ND</td>
<td>None</td>
<td>Full recovery by week 3</td>
</tr>
<tr>
<td>8</td>
<td>F/50</td>
<td>Pfizer (first dose)</td>
<td>Contralateral</td>
<td>4/16</td>
<td>III</td>
<td>Normal</td>
<td>NSAIDs, fentanyl patch, IVMP</td>
<td>Good response to IVMP</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>M/58</td>
<td>Pfizer (first dose)</td>
<td>Ipsilateral</td>
<td>5/30</td>
<td>II</td>
<td>ND</td>
<td>Oral prednisolone, pregabalin</td>
<td>Poor recovery by week 8</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>F/23</td>
<td>Pfizer (first dose)</td>
<td>Ipsilateral</td>
<td>10/11</td>
<td>V</td>
<td>ND (ipsilateral axillary lymphadenopathy in ultrasonography)</td>
<td>ND</td>
<td>Oral prednisolone, pregabalin</td>
<td>Partial recovery within week 6</td>
</tr>
<tr>
<td>11</td>
<td>F/81</td>
<td>Pfizer (first dose)</td>
<td>Bilateral</td>
<td>15 NA</td>
<td>IV</td>
<td>Normal</td>
<td>Pregabalin, norrixiptiline, NSAIDs</td>
<td>Poor recovery by month 6</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>M/39</td>
<td>Moderna (first dose)</td>
<td>Ipsilateral</td>
<td>7/14</td>
<td>IV</td>
<td>Prominent ipsilateral axillary lymph nodes</td>
<td>WBC 1, protein 76</td>
<td>IVMP followed by oral prednisolone, gabapentin</td>
<td>Poor recovery by week 8</td>
</tr>
</tbody>
</table>

*Values were expressed as cells/μL (WBC) and mg/dL (protein).
†Parsonage-Turner syndrome occurred 2 days after Pfizer vaccination following initial AstraZeneca vaccination.
CSF, cerebrospinal fluid; f, female; IVMP, intravenous methylprednisolone; M, male; MRC, Medical Research Council; ND, not done; NSAIDs, non-steroidal anti-inflammatory drugs; WBC, white blood cell.
(patient 4). We noted a variable degree of recovery at the last follow-up: complete in three, partial in four and poor in five.

DISCUSSION
Vaccination is one of the known potential triggers of PTS, with case series and reports for tetanus, smallpox, human papillomavirus, influenza and, recently, COVID-19 vaccines. To date, there have been seven publications reporting 10 cases of PTS following COVID-19 vaccination (online supplemental table). While most of the reported cases (8/10) received mRNA vaccines, our observations implicate the adenoviral vector-based vaccine as well in 6 of 12 cases. The time interval between vaccination and PTS onset ranged from 2 to 16 days, which is in line with previous reports and coincided with the expected time course of the immune response against COVID-19 vaccines. Similar to previous reports, we found that PTS post COVID-19 vaccination mostly takes the classic form, but also observed atypical phenotypes of pure sensory or painless motor-predominant form in two cases.

Intriguingly, we found that PTS occurred on the same side of vaccination in all except two cases. Combined with all previously reported cases, the rate of ipsilateral PTS reaches 77.3% (17 of 22 cases). Meanwhile, we noted an unexpectedly high frequency of ipsilateral reactive lymphadenopathy in our cases (87.5%). Although it has not been addressed in the context of PTS, reactive lymphadenopathy is reportedly a frequent finding at imaging with an incidence of up to 53% with the COVID-19 mRNA vaccines in patients with breast cancer. Taken together, we proposed the need for further research to investigate whether these local immune reactions are involved in the pathogenesis of ipsilateral brachial neuritis or whether they are simply observed together by chance.

It should be emphasised that we cannot establish a robust causal relationship between PTS and COVID-19 vaccination with case series. It is also worth mentioning that the benefits of COVID-19 vaccination far outweigh the potential risks. Corroborating the findings of previous case reports, our observations suggest that COVID-19 vaccines may be associated with PTS characterised by ipsilateral occurrence and possibly accompanied by reactive lymphadenopathy. Further studies are warranted to assess the causality and significance of the ipsilateral association.

REFERENCES

OPEN ACCESS
Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/jnnp-2021-328182).

YGM and J-EK contributed equally.

YGM and J-EK are joint first authors.


Received 13 October 2021
Accepted 23 February 2022
Published Online First 6 April 2022
J Neurol Neurosurg Psychiatry 2022;93:1231–1232.

doi:10.1136/jnnp-2021-328182

ORCID iDs
Young Gi Min http://orcid.org/0000-0002-8091-7585
Jee-Eun Kim http://orcid.org/0000-0002-3811-3479
Yoon-Ho Hong http://orcid.org/0000-0002-3325-6358

Yoon-Ho Hong, College of Medicine, Ewha Womans University Seoul, South Korea
Young Gi Min, College of Medicine, Ewha Womans University, Seoul, South Korea
Jung-Joon Sung, College of Medicine, Ewha Womans University, Seoul, South Korea
Lee-Young Shin, College of Medicine, Ewha Womans University, Seoul, South Korea
Jee-Eun Kim, College of Medicine, Ewha Womans University, Seoul, South Korea
Hyoung Soo Kim, College of Medicine, Ewha Womans University, Seoul, South Korea
Joon Sung, College of Medicine, Ewha Womans University Seoul, South Korea
Eun Kim http://orcid.org/0000-0002-3811-3479
YGM and J-EK prepared the figure. J-YS and J-JS interpreted the data. Y-HH supervised the work.

Funding This work was supported by a focused clinical research grant-in-aid (03-2016-0300) from the Seoul National University Hospital Research Fund.

Competing interests None declared.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval This study involves human participants and was approved by the institutional review boards (IRBs) of Seoul National University Hospital (IRB 2110-049-1261), Seoul Metropolitan Government Boramae Medical Center (IRB 30-2021-122) and Ewha Womans University Seoul Hospital (IRB 2021-09-021). The participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
Supplementary information

Supplementary Figure. Illustrations of the clinical course and magnetic resonance image of the brachial plexus in two representative cases with Parsonage-Turner syndrome post-COVID-19 vaccination. Patient 1 (panel A) presented with moderate weakness in the shoulder abduction (seven days from onset) which rapidly improved over the next five days with the administration of intravenous methylprednisolone. Patient 3 (panel B) had severe weakness of the left hand (49 days from onset, left and middle panels) and left with residual deficits despite oral prednisolone treatment (right). Panel C shows the prominent thickening and signal changes in the inferior trunk of the brachial plexus in patient 3. Ipsilateral prominence of axillary and cervical lymph nodes was noted in four among six patients who underwent MRI evaluation. Representative examples of patient 5 and patient 1 are shown (D-1 and D-2, respectively).
Supplementary Table. Summary of previous case reports of PTS post COVID-19 vaccination.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Journal, Year</th>
<th>Number of cases</th>
<th>Ipsilateral case</th>
<th>Vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Queler SC, et al.</td>
<td>Radiology, 2021</td>
<td>2</td>
<td>1</td>
<td>Pfizer-BioNTech (1), Moderna (1)</td>
</tr>
<tr>
<td>Koh JS, et al.</td>
<td>QJM, 2021</td>
<td>3</td>
<td>2</td>
<td>Pfizer-BioNTech (2), mRNA-1273 (1)</td>
</tr>
<tr>
<td>Diaz-Segarra N, et al.</td>
<td>PM R, 2021</td>
<td>1</td>
<td>0</td>
<td>Pfizer-BioNTech</td>
</tr>
<tr>
<td>Vitturi BK, et al.</td>
<td>J Medical Case Rep, 2021</td>
<td>1</td>
<td>1</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Nawaz SB &amp; Raigam WA</td>
<td>EJMHS, 2022</td>
<td>1</td>
<td>1</td>
<td>mRNA (exact type was not specified)</td>
</tr>
<tr>
<td>Sharma A &amp; Gupta A</td>
<td>Cureus, 2022</td>
<td>1</td>
<td>1</td>
<td>AstraZeneca</td>
</tr>
</tbody>
</table>